Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride improves prostate cancer detection in PSA test.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Ganoderma lucidum may help treat enlarged prostate in rats.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.

Family doctors can manage older men with urinary symptoms using exams, tests, and medications.

Some common medications can lower PSA levels in 45-year-old German men.

Some common medications like metformin, insulin, and ACE inhibitors can lower PSA levels, while statins don't, and low dose finasteride significantly reduces PSA.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

The document concludes that better training and education are needed for proper cancer screening and criticizes the GMC's inaction as harmful to clinical ethics in the UK.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

PSA might help diagnose PCOS and related skin issues, but more research is needed.

PSA levels could help detect illegal steroid use in female athletes but face challenges like cost and PCOS prevalence.

Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

Finasteride effectively treats baldness but may cause sexual side effects.

Men with thinner hair from genetic hair loss may be more likely to have an enlarged prostate.